UBS Group’s Adaptive Biotechnologies ADPT Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $5.31M | Buy |
455,406
+179,789
| +65% | +$2.09M | ﹤0.01% | 3010 |
|
2025
Q1 | $2.05M | Sell |
275,617
-121,641
| -31% | -$904K | ﹤0.01% | 3683 |
|
2024
Q4 | $2.38M | Buy |
397,258
+324,107
| +443% | +$1.94M | ﹤0.01% | 3586 |
|
2024
Q3 | $375K | Buy |
73,151
+16,520
| +29% | +$84.6K | ﹤0.01% | 4288 |
|
2024
Q2 | $205K | Sell |
56,631
-86,984
| -61% | -$315K | ﹤0.01% | 4532 |
|
2024
Q1 | $461K | Buy |
143,615
+11,095
| +8% | +$35.6K | ﹤0.01% | 4159 |
|
2023
Q4 | $649K | Buy |
132,520
+42,202
| +47% | +$207K | ﹤0.01% | 3772 |
|
2023
Q3 | $492K | Sell |
90,318
-12,023
| -12% | -$65.5K | ﹤0.01% | 3611 |
|
2023
Q2 | $687K | Buy |
102,341
+15,483
| +18% | +$104K | ﹤0.01% | 3574 |
|
2023
Q1 | $767K | Buy |
86,858
+24,722
| +40% | +$218K | ﹤0.01% | 3387 |
|
2022
Q4 | $475K | Buy |
62,136
+35,131
| +130% | +$268K | ﹤0.01% | 3744 |
|
2022
Q3 | $193K | Buy |
27,005
+1,725
| +7% | +$12.3K | ﹤0.01% | 4084 |
|
2022
Q2 | $205K | Sell |
25,280
-24,372
| -49% | -$198K | ﹤0.01% | 3916 |
|
2022
Q1 | $690K | Buy |
49,652
+50
| +0.1% | +$695 | ﹤0.01% | 3540 |
|
2021
Q4 | $1.39M | Sell |
49,602
-2,456
| -5% | -$68.9K | ﹤0.01% | 3178 |
|
2021
Q3 | $1.77M | Buy |
52,058
+36,761
| +240% | +$1.25M | ﹤0.01% | 2830 |
|
2021
Q2 | $625K | Sell |
15,297
-6,684
| -30% | -$273K | ﹤0.01% | 3593 |
|
2021
Q1 | $885K | Sell |
21,981
-986
| -4% | -$39.7K | ﹤0.01% | 3478 |
|
2020
Q4 | $1.36M | Sell |
22,967
-3,711
| -14% | -$219K | ﹤0.01% | 2928 |
|
2020
Q3 | $1.3M | Buy |
26,678
+3,666
| +16% | +$178K | ﹤0.01% | 2755 |
|
2020
Q2 | $1.11M | Sell |
23,012
-3,706
| -14% | -$179K | ﹤0.01% | 2740 |
|
2020
Q1 | $742K | Buy |
26,718
+16,788
| +169% | +$466K | ﹤0.01% | 2899 |
|
2019
Q4 | $297K | Sell |
9,930
-2,211
| -18% | -$66.1K | ﹤0.01% | 4318 |
|
2019
Q3 | $375K | Buy |
+12,141
| New | +$375K | ﹤0.01% | 3925 |
|